VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma

Keywords

Anorexia, Medicine, Internal medicine

References

• Prognostic significance of morphologic parameters in renal cell carcinomaIlán Stavans — 1982
• Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.Taro Shuin, Keiichi Kondo, Soichiro Torigoe — 1994
• Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaLucy Gossage, Muhammed Murtaza, Andrew F. Slatter — 2014
• Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.H. Nekarda, Manfred Schmitt, Kurt Ulm — 1994
• Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.Subbian Ananth, Bertrand Knebelmann, W Grüning — 1999
• Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal NeoplasmsNing Yi Yap, Retnagowri Rajandram, Keng Lim Ng — 2015
• Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinomaAlison C. Young, Rachel A. Craven, D. Cohen — 2009
• pVHL: A Multipurpose Adaptor ProteinIan J. Frew, Wilhelm Krek — 2008
• TGFβ signalling in contextJoan Massagué — 2012
• Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.M. Fredstorp-Lidebring, Pär‐Ola Bendahl, Nils Brünner — 2001
• Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parametersKeiichi Kondo, Masahiro Yao, Minoru Yoshida — 2002
• Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomyDragomir P. Zubac, Tore Wentzel‐Larsen, Tomas Seidal — 2010
• VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinomaPeter Schraml, Kirsten Struckmann, Florian Hatz — 2002
• The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent mannerAlessandro Sorrentino, Noopur Thakur, Susanne Grimsby — 2008
• Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.John S. Lam, Tobias Klatte, Jean‐Jacques Patard — 2007
• Inhibitory PAS Domain Protein (IPAS) Is a Hypoxia-inducible Splicing Variant of the Hypoxia-inducible Factor-3α Locus*Yuichi Makino, Arvydas Kanopka, W.J. Wilson — 2002
• Non-Smad signaling pathwaysYabing Mu, Shyam Kumar Gudey, Maréne Landström — 2011
• TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancerYabing Mu, Reshma Sundar, Noopur Thakur — 2011
• Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?Sabine Brookman‐May, Matthias May, Ingmar Wolff — 2015
• Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma.Ulrika Svenson, Börje Ljungberg, Göran Roos — 2009

Cited by

• miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell CarcinomaXue Gong, Hongjuan Zhao, Matthias Saar — 2019
• miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinomaChuanshan Zang, Jian Sun, Wenyi Liu — 2019
• Interactions between TGF-β type I receptor and hypoxia-inducible factor-α mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinomaPramod Mallikarjuna, Raviprakash T. Sitaram, Karthik Aripaka — 2019
• Hypoxia-induced epithelial to mesenchymal transition in cancerRobert Hapke, Scott M. Haake — 2020
• Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney DiseasesTingting Li, Chao Yu, Shougang Zhuang — 2021
• The Most Common VHL Point Mutation R167Q in Hereditary VHL Disease Interferes with Cell Plasticity RegulationStéphanie Buart, Stéphane Terry, M’Boyba Diop — 2021
• pVHL-mediated SMAD3 degradation suppresses TGF-β signalingJun Zhou, Yasamin Dabiri, Rodrigo A. Gama-Brambila — 2021
• The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and FibrosisPramod Mallikarjuna, Yang Zhou, Maréne Landström — 2022
• The precision medicine approach to cancer therapy: part 1 — solid tumoursBenjamin R. Challoner, D. Thurston — 2019
• The Tumor Microenvironment of Clear-Cell Ovarian CancerMichael-John Devlin, Rowan Miller, Florian Laforêts — 2022
• The cross‐talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cellsSofia De Marco, B Torsello, Emanuela Minutiello — 2022
• A Boolean network model of hypoxia, mechanosensing and TGF-β signaling captures the role of phenotypic plasticity and mutations in tumor metastasisGL Greene, Ian Zonfa, Erzsébet Ravasz Regan — 2024
• Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancerPramod Mallikarjuna, Cemal Erdem, Ruben Ilundain Beorlegui — 2025
• Von Hippel–Lindau/Hypoxia Inducible Factor Axis in GlioblastomaItamar Flores, Alelí Salazar, Verónica Pérez de la Cruz — 2025
• pVHL status in clear cell renal cell carcinoma regulates HIF-α and E-cadherin expression levels and their implications for tumor progressionRaviprakash T. Sitaram, Börje Ljungberg — 2025
• Prognostic gene screening and experimental validation in renal clear cell carcinoma based on spatial transcriptomics and single-cell sequencingCong Fu, Lin Sun, Tong Zhou — 2026
• The role of transforming growth factor ‐ β signaling and hypoxia ‐ inducible factors in renal cell carcinoma2019

Related papers

No related papers recorded.